Skip to Content

GenMark 

" Our expertise is in the design, development, and commercialization of molecular systems and assays based on our proprietary electrochemical detection technology "

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​About Us

GenMARK is a leader in molecular diagnostics, providing advanced DNA and PCR-based testing solutions that support data-driven decision-making in the field of genetics. With a portfolio of high-precision genotype assays, we empower producers and professionals to monitor, manage, and optimize biological performance ​

The Merle Gene: A Unique Genetic Pattern  

The Merle gene is a genetic mutation most commonly observed in dogs, though it can also appear in other species like cats and horses. This gene produces a distinct coat color pattern characterized by irregular patches of diluted pigment over a solid base coat. The result is a marbled or mottled appearance that is often accompanied by blue or partially blue eyes and sometimes depigmented areas on the skin and nose. The gene responsible for this effect is a variant of the PMEL gene, which plays a role in melanin production and distribution in the cells.  


Merle: Where Beauty Meets Bioethics

As genomics enters a new era of precision and predictive biology, the Merle gene offers more than just a lesson in coat color it becomes a model for studying gene-expression balance and phenotypic risk management. Beyond its visual allure, Merle represents a live interface between aesthetics and pathology, forcing us to rethink how single-gene variants can ripple through complex biological systems. Future innovations may harness gene-editing tools not to eliminate such traits, but to modulate their expression safely, preserving diversity while preventing harm. In this light, Merle is not merely a mutation it’s a bioethical checkpoint, a genetic signature that challenges us to design reproductive strategies informed by both heritage and health foresight.

Learn More


In the age of precision biology, the Merle gene emerges not just as a pigment-altering mutation, but as a genetic signal embedded in living design a visible manifestation of the complex interplay between aesthetics and vulnerability. Its striking marbled pattern, long admired in selective breeding, conceals a deeper narrative of developmental balance and systemic fragility. As genomic tools like CRISPR and predictive sequencing advance, Merle may evolve into a case study for how we navigate traits that lie at the intersection of desirability and dysfunction. Rather than erasing such traits, the challenge lies in harnessing molecular insight to preserve diversity responsibly, opening new doors for ethical innovation in animal genetics.

In parallel with our advancements in DNA-based technologies, antibody testing is emerging as another powerful tool .

  ​ ​

 Antibody Profiling: A Cornerstone of Modern Livestock Health Management 

Antibody profiling in livestock has become an indispensable tool for epidemiological surveillance, vaccine monitoring, and early detection of subclinical infections. High-throughput serological assays enable rapid screening of herd-level immune responses, offering insights into pathogen circulation, vaccination efficacy, and immunization coverage. Particularly in large-scale farming systems, antibody-based diagnostics—such as ELISA, competitive immunoassays, and multiplex bead-based platforms—facilitate proactive health strategies by detecting past and ongoing infections even in asymptomatic animals. These assays are crucial for managing zoonotic risks, verifying maternal antibody transfer, and guiding precision vaccination schedules. As disease dynamics evolve under pressure from climate change, trade, and antibiotic reduction policies, integrating antibody surveillance into herd health programs is key to maintaining resilience and productivity in animal populations.


Next-Generation Antibody Assays: Speed, Sensitivity, and Scale  

Modern serological technologies have significantly advanced the detection of antibodies in veterinary diagnostics, offering both sensitivity and scalability. Enzyme-Linked Immunosorbent Assays (ELISA) remain the gold standard for quantitative antibody detection, valued for their robustness, adaptability, and cost-efficiency in high-throughput settings. Chemiluminescence immunoassays (CLIA), leveraging light-emitting reactions for antigen-antibody detection, offer superior sensitivity and dynamic range, making them ideal for detecting low-abundance antibodies. Meanwhile, lateral flow devices (LFDs) provide rapid, on-site results without the need for laboratory infrastructure, making them particularly useful for field applications and point-of-care decision-making. The automation of ELISA and CLIA platforms allows simultaneous processing of hundreds to thousands of samples, drastically reducing turnaround times and minimizing human error. These technologies are now essential components of large-scale herd health monitoring, enabling timely interventions, optimized vaccination strategies, and early outbreak detection in both commercial and smallholder farming systems.

Digital Immunity: How Technology Is Transforming Antibody Testing

The integration of digital technologies into immunodiagnostics is revolutionizing the way antibody testing is performed, interpreted, and applied. From automated high-throughput ELISA platforms to portable lateral flow readers linked to cloud-based analytics, modern tools now enable real-time, large-scale immune surveillance with unprecedented accuracy and speed. Advanced imaging systems, machine learning algorithms, and IoT-enabled diagnostics allow for precise quantification and pattern recognition of antibody responses, even in complex biological samples. These innovations are not only streamlining workflows in laboratories and field settings but also transforming raw serological data into actionable insights for disease monitoring, vaccine efficacy, and population-level immunity mapping. As digital immunity becomes central to modern diagnostics, antibody testing is evolving from a static endpoint into a dynamic, data-rich process driving predictive and preventive strategies.

Learn More


Smart Immunodiagnostics: How Digital Tech is Advancing Antibody Analysis?






Digital innovation is transforming antibody analysis into a faster, smarter, and more precise science empowering better health decisions worldwide

Digital transformation is reshaping antibody testing from manual, time-consuming procedures into streamlined, intelligent systems. Innovations such as multiplex immunoassays, cloud-connected biosensors, and AI-powered data interpretation are enhancing sensitivity while reducing turnaround time.


These technologies not only detect multiple antibodies simultaneously but also provide comprehensive immune profiles with minimal sample input. In research, clinical, and diagnostic settings, digital platforms facilitate longitudinal immune monitoring, early outbreak detection, and precision vaccination strategies. The convergence of immunology and digital infrastructure marks a new era where antibody data becomes faster to obtain, easier to interpret, and more impactful in driving timely and informed decisions across healthcare and biosecurity sectors.

Learn More


From Exposure to Immunity: Tracking Livestock Health Through Antibodies


Antibody profiling serves as a robust biomarker for assessing both pathogen exposure and the development of adaptive immunity within livestock populations. Using  high-sensitivity serological assays such as ELISA, multiplex immunoassays, and chemiluminescence-based platforms, researchers can quantitatively evaluate specific immunoglobulin isotypes indicative of recent or past infections. This approach facilitates the detection of subclinical infections, informs on vaccine-induced seroconversion, and enables longitudinal monitoring of herd immunity dynamics. By integrating antibody data with epidemiological models, it becomes possible to predict outbreak risks, optimize immunization schedules, and implement precision health interventions. Such antibody-based surveillance not only enhances disease control strategies but also supports sustainable livestock management in the face of emerging pathogens and evolving environmental pressures.

Multiplexing Immunity: Simultaneous Antibody 

Multiplex immunoassays represent a transformative advance in serological testing by enabling the simultaneous detection and quantification of multiple antibody specificities within a single sample. This technology leverages microsphere- or bead-based platforms coupled with fluorescence or chemiluminescence readouts, allowing comprehensive immune profiling across diverse pathogens or antigen targets. Multiplexing not only improves assay throughput and reduces sample volume requirements but also provides a multidimensional view of immune status, critical for differentiating vaccine responses from natural infections and assessing cross-reactivity. By delivering rich datasets on antibody breadth and magnitude, multiplex assays enhance diagnostic accuracy and support data-driven decision-making in disease surveillance, vaccine efficacy evaluation, and herd health management. This integrated approach is especially valuable in complex epidemiological contexts where co-infections and antigenic variation challenge traditional single-target assays.

Discover

Multiplexed Electrochemical Immunosensors for Clinical Biomarkers

This study introduces a novel electrochemical multiplex sensor designed for the simultaneous detection of celiac disease biomarkers. The system utilizes a dual-sensor platform based on screen-printed carbon electrodes modified with carbon nanotubes and gold nanoparticles. These nanomaterials enhance the surface area and conductivity of the electrodes, allowing for efficient immobilization of gliadin and tissue transglutaminase antigens. By detecting both IgA and IgG antibodies in a single assay, the sensor offers a comprehensive serological profile. The use of enzyme-labeled secondary antibodies and a silver deposition step amplifies the electrochemical signal, enabling sensitive and specific identification of immune responses associated with celiac disease—all within a single, integrated platform.


Let's Connect

Submit